



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Chloroquine or hydroxychloroquine for prophylaxis of COVID-19

Published Online  
April 17, 2020  
[https://doi.org/10.1016/S1473-3099\(20\)30296-6](https://doi.org/10.1016/S1473-3099(20)30296-6)

In-vitro studies have shown that chloroquine is effective against several viruses, including severe acute respiratory syndrome coronavirus (SARS-CoV).<sup>1</sup> Multiple mechanisms of action have been identified for chloroquine that disrupt the early stage of coronavirus replication. Moreover, chloroquine affects immune system activity by mediating an anti-inflammatory response, which might reduce damage due to the exaggerated inflammatory response.<sup>1</sup> At the time of the SARS epidemic, chloroquine was suggested as a drug that could be used to treat this infection.<sup>2</sup> However, randomised, double-blind, controlled studies in humans to evaluate its efficacy for this use were not done, and the true clinical efficacy of chloroquine in treating coronavirus infections was not established.

Because coronavirus disease 2019 (COVID-19) is associated with substantial morbidity and mortality,<sup>3</sup> and no specific pharmacological treatment that is effective against it is available, chloroquine and chloroquine-related formulations have been tentatively included among drugs for use in limiting the total burden of COVID-19.<sup>4,5</sup> However, no studies have evaluated the use of chloroquine for prophylaxis.

Chloroquine is a cheap drug that has been used for decades—predominantly for malaria prophylaxis, for which it had excellent results and good safety and tolerability.<sup>1</sup> Severe adverse events, which mainly involve retinal and psychiatric symptoms, occur only when doses prescribed for malaria are substantially higher than required.<sup>1</sup> Inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication seems essential to reduce the risk of spread and development of COVID-19. SARS-CoV-2 is highly

contagious.<sup>5</sup> Most people who live in areas with a high incidence of COVID-19 are apparently healthy, but they can be SARS-CoV-2 negative and healthy or healthy but with asymptomatic infection. In both cases, effective drugs such as chloroquine and its related formulations might prevent infection (ie, in those who are SARS-CoV-2 negative) or the development of severe symptomatic disease (ie, in those who are SARS-CoV-2 positive and asymptomatic or with minor symptoms), substantially reducing morbidity and mortality due to COVID-19. The dose used might be the same as that usually administered for malaria treatment given chloroquine inhibited SARS-CoV replication at a 50% effective concentration of 8.8 µmol/L. The half-maximal inhibitory concentration (IC<sub>50</sub>) of chloroquine inhibition of SARS-CoV replication in Vero E6 cells, 8.8 µmol/L, is substantially lower than the plasma concentrations that are reached in humans when the drug is prescribed to treat malaria at a dose of 25 mg/kg over 3 days.<sup>1</sup> For long-term prophylaxis, even lower doses could be used. Doses of 3–6 mg/kg, similar to those generally prescribed to treat rheumatoid arthritis, lead to plasma concentrations of 1–3 µmol/L—ie, the same concentration range as the IC<sub>50</sub> for SARS-CoV inhibition.<sup>1</sup> Alternatively, hydroxychloroquine could be used, for which even greater efficacy has been reported in in-vitro studies.<sup>5</sup> Prophylaxis could last for the whole duration of an outbreak, and in countries in which malaria is not endemic, there is no risk of negative events associated with the development of resistance to this drug. In countries where malaria is endemic, appropriate monitoring of resistance among *Plasmodium* spp is needed.

Future studies might better elucidate the most effective schedule of administration and potential adverse events. We advocate for studies to evaluate whether

chloroquine or hydroxychloroquine prophylaxis should be considered in a country such as Italy, where there are thousands of cases and deaths as a result of COVID-19.

We declare no competing interests.

Nicola Principi, \*Susanna Esposito  
[susanna.esposito@unimi.it](mailto:susanna.esposito@unimi.it)

Università degli Studi di Milano, Milan Italy (NP);  
Paediatric Clinic, Pietro Barilla Children's Hospital,  
University of Parma, 43126 Parma, Italy (SE)

- 1 Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis* 2003; **3**: 722–27.
- 2 Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect* 2017; **5**: e00293.
- 3 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
- 4 Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 2020; published online March 10. DOI:10.1016/j.jcrrc.2020.03.005.
- 5 Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020; published online March 9. DOI:10.1093/cid/ciaa237.

## Hydroxychloroquine prophylaxis for COVID-19 contacts in India

More than a billion Indians currently stand at the precipice of a massive increase in cases of coronavirus disease 2019 (COVID-19). India had shown a staggered course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, with 1397 cases diagnosed between Jan 31, and April 1, 2020. However, there has been a recent surge in cases, with numbers rising to 5194 as of April 8.<sup>1</sup>

The Indian Council of Medical Research, under the Ministry of Health and Family Welfare, has recommended chemoprophylaxis with hydroxychloroquine (400 mg



Published Online  
April 17, 2020  
[https://doi.org/10.1016/S1473-3099\(20\)30313-3](https://doi.org/10.1016/S1473-3099(20)30313-3)